Normal Physiologic and Benign Foci with F-18 FDG Avidity on PET/CT in Patients with Breast Cancer

Park, Soon-Ah; Lee, Kwangman; Choi, Un-Jong; Kim, Hun Soo; Kim, Hye-Won; Song, Jeong‐Hoon

doi:10.1007/s13139-010-0055-7

Cited by 10 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although 18 F-FDG PET/CT shows a low false-positive rate for the staging of breast cancer, careful attention must be paid to normal or altered physiological 18 F-FDG uptake patterns and benign hypermetabolic disease, in order to avoid misinterpretations. As observed in the present study, the most common sites of increased 18 F-FDG uptake in female patients with breast cancer are the thyroid glands, where hypermetabolic disease occurs, and the ovary/uterus, where there is normal physiological uptake ( 21 ) . However, abnormal 18 F-FDG uptake should be evaluated in order to exclude metastases and non-breast second primary tumors, which are occasionally encountered in breast cancer patients ( 22 , 23 ) .…”

Section: Discussionsupporting

confidence: 68%

Detection of distant metastases in patients with locally advanced breast cancer: role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging with computed tomography scans

et al. 2017

View full text Add to dashboard Cite

ObjectiveTo evaluate positron emission tomography/computed tomography (PET/CT) and conventional imaging tests for the detection of distant metastases in patients with locally advanced breast cancer.Materials and methodsWe included 81 patients with breast cancer who had undergone 18F-fluorodeoxyglucose (FDG) PET/CT before treatment. Conventional imaging included the following: bone scintigraphy; chest X-ray (in 14.5%) or CT (in 85.5%); and abdominal ultrasound (in 10.8%), CT (in 87.8%), or magnetic resonance imaging (in 1.4%). Histopathology and clinical/imaging follow-up served as reference.ResultsDistant metastases were observed in nine patients (11.1%). On patient-based analysis, conventional imaging identified distant metastases in all 9 patients. In one patient, the initial 18F-FDG PET/CT failed to demonstrate bone metastases that was evident on bone scintigraphy. In two patients, the CT scan failed to show extra-axillary lymph node metastases that were identified on 18F-FDG PET/CT. There was no significant difference between 18F-FDG PET/CT and conventional imaging in terms of their sensitivity for the detection of distant metastases in patients with locally advanced breast cancer.ConclusionThis study showed that 18F-FDG PET/CT and conventional imaging with CT scans had similar sensitivity for the diagnosis of distant metastases in patients with locally advanced breast cancer. 18F-FDG PET/CT can add information about extra-axillary lymph node involvements.

show abstract

Section: Discussionsupporting

confidence: 68%

Detection of distant metastases in patients with locally advanced breast cancer: role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging with computed tomography scans

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In a number of cases, the intensity of FDG accumulation is used to differentiate between malignant and benign lesions (23)(24)(25)(26). However, numerous other benign conditions, including abscess, pulmonary granuloma, tuberculosis and sarcoidosis, may also present with increased 18 F-FDG uptake (23,(27)(28)(29)(30)(31)(32). Thus, there is a high chance of encountering false-positive conditions in a clinical setting.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic clue of nodular fasciitis mimicking metastasis in papillary thyroid cancer, mismatching findings on 18F-FDG PET/CT and 123I whole body scan: A case report

Seo

Kim

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. This study reports a case of nodular fasciitis incidentally detected in a patient with papillary thyroid cancer. A 47-year-old woman underwent a total thyroidectomy and radioactive iodine therapy for papillary thyroid cancer. On a follow-up fluorodeoxyglucose ( 18 F-FDG) PET/computed tomography (CT) scan after 12 months, a focal 18 F-FDG-avid lesion was incidentally detected in the paraspinal muscle. It was well-enhanced on CT and magnetic resonance imaging, indicating metastasis. However, the lesion was not iodine avid on the 123 I whole body scan, which favored benign etiology over metastasis from thyroid cancer. For pathological confirmation, surgical excision was performed and the paraspinal lesion was finally confirmed as nodular fasciitis. Therefore, it was suggested that nodular fasciitis may be included in the differential diagnosis of a 18 F-FDG avid/iodine non-avid soft tissue lesion in patients with thyroid cancer. In such circumstances, 123I whole body scans may serve a role in non-invasive work-up, and prevent unnecessary surgical procedures.

show abstract

“…When a 2-[ 18 F]FDG-avid breast lesion is incidentally detected in a study performed for reasons other than BC, further characterization with diagnostic mammography and/ or breast US should be performed because these lesions are malignant in 30-40% of cases [62,63]. Several aetiologies have been described, including unsuspected BC, lymphoma, and metastases [59,[64][65][66][67].…”

Section: Incidental Breast Findings With 2-[ 18 F]fdg Uptake and Addi...mentioning

confidence: 99%

Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer

Vaz,

Woll,

Cardoso

et al. 2024

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Introduction There is much literature about the role of 2-[18F]FDG PET/CT in patients with breast cancer (BC). However, there exists no international guideline with involvement of the nuclear medicine societies about this subject. Purpose To provide an organized, international, state-of-the-art, and multidisciplinary guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and representation of important societies in the field of BC (ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Methods Literature review and expert discussion were performed with the aim of collecting updated information regarding the role of 2-[18F]FDG PET/CT in patients with no special type (NST) BC and summarizing its indications according to scientific evidence. Recommendations were scored according to the National Institute for Health and Care Excellence (NICE) criteria. Results Quantitative PET features (SUV, MTV, TLG) are valuable prognostic parameters. In baseline staging, 2-[18F]FDG PET/CT plays a role from stage IIB through stage IV. When assessing response to therapy, 2-[18F]FDG PET/CT should be performed on certified scanners, and reported either according to PERCIST, EORTC PET, or EANM immunotherapy response criteria, as appropriate. 2-[18F]FDG PET/CT may be useful to assess early metabolic response, particularly in non-metastatic triple-negative and HER2+ tumours. 2-[18F]FDG PET/CT is useful to detect the site and extent of recurrence when conventional imaging methods are equivocal and when there is clinical and/or laboratorial suspicion of relapse. Recent developments are promising. Conclusion 2-[18F]FDG PET/CT is extremely useful in BC management, as supported by extensive evidence of its utility compared to other imaging modalities in several clinical scenarios.

show abstract

Normal Physiologic and Benign Foci with F-18 FDG Avidity on PET/CT in Patients with Breast Cancer

Cited by 10 publications

References 18 publications

Detection of distant metastases in patients with locally advanced breast cancer: role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging with computed tomography scans

Detection of distant metastases in patients with locally advanced breast cancer: role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging with computed tomography scans

Diagnostic clue of nodular fasciitis mimicking metastasis in papillary thyroid cancer, mismatching findings on 18F-FDG PET/CT and 123I whole body scan: A case report

Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer

Contact Info

Product

Resources

About